Regenerative biologics supplier for orthopedic practices in Boston, MA

How orthopedic practices structure vendor qualification

Orthopedic practices and ambulatory surgery centers typically route a new biologics vendor through a compliance or practice-management review before any product reaches a shelf. That review generally covers vendor licensure and registration documentation, lot-specific testing records, and a description of how the supplier screens and processes donor tissue.

Precision Biologics provides a certificate of analysis, a donor eligibility summary, and a lot release record for each lot on request, so a practice's review can proceed against documentation rather than marketing claims.

NPI-verified accounts

Orders are limited to licensed healthcare professionals, and account verification requires a valid NPI number checked against the NPPES registry. This applies to solo orthopedic offices and multi-surgeon ambulatory surgery centers in Boston alike; the account structure does not change based on practice size.

• NPI number required at account setup
• Verification applies per provider or per group, depending on how the practice bills
• Account access does not substitute for a practice's own credentialing of its vendors

Cold-chain shipping to Massachusetts

Cryopreserved products are slow-frozen, stored at -80 degrees Celsius, and shipped overnight on dry ice in validated containers, with lot numbers tracked from shipment through delivery. Practices receiving shipments in Boston should have a designated person confirm cold-chain integrity on arrival and log the lot number against the patient record, consistent with standard HCT/P traceability practice.

Lyophilized formats ship at ambient conditions and are handled according to the storage instructions in the product insert supplied with each lot.

Confirming regulatory posture before ordering

Whether a specific intended use for a Wharton's jelly product qualifies under 21 CFR 1271.10, or how a practice should treat an exosome product regulated as a biologic drug, is a determination for the practice and its own counsel, not Precision Biologics. We recommend Boston practices confirm vendor relationships and intended-use questions with the Massachusetts Board of Registration in Medicine and with legal counsel before finalizing a purchasing decision.

Precision Biologics supports account setup, documentation requests, and peer-to-peer conversations about product records; we do not provide clinical or legal advice.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.